Clinical Trials Logo

Filter by:
NCT ID: NCT04868006 Completed - Clinical trials for Sports Physical Therapy

End-range Maitland Mobilization on Glenohumeral Internal Rotation Deficit and Proprioception

Start date: September 28, 2021
Phase: N/A
Study type: Interventional

Glenohumeral internal rotation deficit (GIRD) is one of the main reasons for glenohumeral pain in athletes with over-head activity. As GIRD increases, the ratio between internal and external rotation changes resulting in decreased joint stability. Joint mobilization is a possible option for the decrease of GIRD and contribution to improvement of proprioception in addition to physical therapy. The aim of this trial is to investigate the effect of end-range Maitland mobilization in addition to physical therapy on GIRD, other joint movements and proprioception.

NCT ID: NCT04864834 Completed - Clinical trials for Neovascular Age-related Macular Degeneration

Phase III Study Assessing the Efficacy, Safety and Immunogenicity of SOK583A1 Versus Eylea® in Patients With Neovascular Age-related Macular Degeneration

Mylight
Start date: May 12, 2021
Phase: Phase 3
Study type: Interventional

Purpose and rationale: To demonstrate similar efficacy, safety and immunogenicity of SOK583A1 and Eylea EU as per Eylea approved treatment regimen in patients with nAMD. The primary clinical question of interest is: Does SOK583A1 have similar efficacy as Eylea EU in terms of mean change in BCVA score in participants with nAMD who are anti-VEGF naive, without important protocol deviations and adherent to the treatment and completed the treatment to Week 8?

NCT ID: NCT04857385 Completed - Clinical trials for Radial Artery Hemostasis

Radial Artery Puncture Hemostasis Study

RAPHE
Start date: April 14, 2021
Phase: N/A
Study type: Interventional

RAPHE is an open label randomized clinical trial to assess physical, biological and chemical methods of radial artery puncture hemostasis following coronary catheterization. A total of 600 subjects will be randomized in a 1:1:1 fashion to either the StatSeal, Axiostat or TR Band hemostasis devices. Follow-up of the subject will take place 60 days after the index procedure.

NCT ID: NCT04857242 Completed - Brain Death Clinical Trials

Electrical Impedance Tomography Measurements During Apnea Test in Patients With Suspected Brain Death

Start date: April 1, 2021
Phase: N/A
Study type: Interventional

Apnea testing is the final decisive examination in the strictly regulated process of brain death assessment. There is no standardized method found in the literature for apnea testing except for the inspection of possible spontaneous chest movements. In addition, the test itself lasts for several minutes leading to the collapse of the lungs. Electrical impedance tomography (EIT) is a non-invasive, real-time monitoring technique, which is suitable for detecting changes in lung volumes during ventilation. With its help, one can examine the spontaneous initiation of inspiration, the development of atelectasis and the reopening of collapsed regions by mechanical ventilation. Furthermore, the apnea test provides for analysing the effect of changes in pulmonary perfusion on impedance in the absence of noise generated by ventilation.

NCT ID: NCT04854837 Completed - Covid19 Clinical Trials

Safety of Remdesivir Treatment in COVID-19 Patients Requiring Hemodialysis

REM-HD
Start date: April 12, 2021
Phase:
Study type: Observational

The FDA approved the antiviral drug remdesivir for use in adults for the treatment of COVID-19 requiring hospitalization. There are only limited data about the safety of the drug in hemodialysed patents. Chronic kidney disease is a risk factor in COVID-19 for developing severe disease. The aim of our investigation is to observe the safety of remdesivir among hemodialysed patients requiring hospitalization for COVID-19. We are going to compare two group's data: 1. Hemodialysed COVID-19 patients requiring hospitalization because of pneumonia and need of oxygen supplementation, and admitted after 12/Apr/2021 - these patients received remdesivir. 2. Hemodialysed COVID-19 patients requiring hospitalization because of pneumonia and need of oxygen supplementation, and admitted before 12/Apr/2021 - these patients did not receive remdesivir.

NCT ID: NCT04854239 Completed - Partial-edentulism Clinical Trials

Accuracy of Half-guided Implant Placement

Start date: January 1, 2017
Phase: Phase 4
Study type: Interventional

The aim of the present prospective randomized controlled study is to compare the accuracy of implant placement performed either with a surgical motor or a torque wrench as part of a half-guided surgical protocol after maxillary sinus floor augmentation.

NCT ID: NCT04843488 Completed - Dental Implants Clinical Trials

Effectiveness of Different Membrane Applications in Vertical Ridge Augmentation

Start date: April 15, 2021
Phase: N/A
Study type: Interventional

This randomized clinical trial (RCT) study investigates if there is any difference in complication rate between perforated dense-polytetrafluroethylene (d-PTFE) mesh vs perforated d-PTFE mesh covered with a native collagen membrane. The primary endpoint is complication rate. The secondary endpoints are regeneration rate and pseudoperiosteum formation.

NCT ID: NCT04842604 Completed - Clinical trials for Acute Myeloid Leukemia

Continuation Study of B1371019(NCT03416179) and B1371012(NCT02367456) Evaluating Azacitidine With Or Without Glasdegib In Patients With Previously Untreated AML, MDS or CMML

Start date: May 17, 2021
Phase: Phase 3
Study type: Interventional

An open-label study available to all eligible participants from Study B1371019 and participants originating from Study B1371012 continuing on study intervention with azacitidine with or without glasdegib.

NCT ID: NCT04836858 Completed - Atopic Dermatitis Clinical Trials

A Study to Assess the Efficacy and Safety of CMK389 in Patients With Moderate to Severe Atopic Dermatitis.

Start date: April 20, 2021
Phase: Phase 2
Study type: Interventional

The main purpose of this phase 2 study was to assess the efficacy and safety of CMK389 in patients with atopic dermatitis.

NCT ID: NCT04836182 Completed - Clinical trials for Chronic Heart Failure With Reduced Ejection Fraction

A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx in Participants With Chronic Heart Failure With Reduced Ejection Fraction

ASTRAAS-HF
Start date: June 8, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the effect of IONIS-AGT-LRX weekly subcutaneous (SC) injection on plasma angiotensinogen (AGT) concentration from Baseline to Study Day 85 (Week 13) and to evaluate the effect of IONIS-AGT-LRx weekly SC injection on plasma AGT concentration and N-terminal prohormone of B-type natriuretic peptide (NT-proBNP) levels at each scheduled visit in chronic heart failure participants with reduced ejection fraction (HFrEF).